TW201117825A - Compositions and methods for the therapy and diagnosis of influenza - Google Patents

Compositions and methods for the therapy and diagnosis of influenza Download PDF

Info

Publication number
TW201117825A
TW201117825A TW099127135A TW99127135A TW201117825A TW 201117825 A TW201117825 A TW 201117825A TW 099127135 A TW099127135 A TW 099127135A TW 99127135 A TW99127135 A TW 99127135A TW 201117825 A TW201117825 A TW 201117825A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
amino acid
acid sequence
domain
Prior art date
Application number
TW099127135A
Other languages
English (en)
Chinese (zh)
Inventor
Andres G Grandea Iii
Gordon King
Thomas Cox
Ole Olsen
Jennifer Mitcham
Matthew Moyle
Phil Hammond
Original Assignee
Theraclone Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclone Sciences Inc filed Critical Theraclone Sciences Inc
Publication of TW201117825A publication Critical patent/TW201117825A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
TW099127135A 2009-08-14 2010-08-13 Compositions and methods for the therapy and diagnosis of influenza TW201117825A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23415409P 2009-08-14 2009-08-14

Publications (1)

Publication Number Publication Date
TW201117825A true TW201117825A (en) 2011-06-01

Family

ID=43586846

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099127135A TW201117825A (en) 2009-08-14 2010-08-13 Compositions and methods for the therapy and diagnosis of influenza

Country Status (7)

Country Link
US (1) US8974788B2 (enExample)
EP (1) EP2464383A4 (enExample)
JP (2) JP2013501807A (enExample)
AU (1) AU2010282415A1 (enExample)
CA (1) CA2771105A1 (enExample)
TW (1) TW201117825A (enExample)
WO (1) WO2011019932A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI867224B (zh) * 2020-06-08 2024-12-21 中央研究院 重組抗體或片段，以及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008321016B2 (en) * 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20140012098A (ko) * 2011-02-14 2014-01-29 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
JP2014509591A (ja) * 2011-03-15 2014-04-21 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP2016519688A (ja) * 2013-04-22 2016-07-07 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
WO2015082600A1 (en) * 2013-12-05 2015-06-11 Crucell Holland B.V. Process for preparing influenza vaccines
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US20180179265A1 (en) * 2015-04-27 2018-06-28 The Trustees Of The University Of Pennsylvania Engineered human anti-aav antibodies and uses thereof
WO2021011544A1 (en) * 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022132710A1 (en) * 2020-12-15 2022-06-23 Vanderbilt University Human hendra virus and nipah virus antibodies and methods of use therefor
CR20230312A (es) 2021-01-14 2023-08-31 Gilead Sciences Inc Vacunas contra el vih y métodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101522210B (zh) * 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
AU2008321016B2 (en) * 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2743306A1 (en) * 2008-11-12 2010-05-20 Theraclone Sciences, Inc. Human m2e peptide immunogens
US8080244B2 (en) * 2008-11-21 2011-12-20 Los Alamos National Security, Llc Anti-influenza M2e antibody

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI867224B (zh) * 2020-06-08 2024-12-21 中央研究院 重組抗體或片段，以及其用途

Also Published As

Publication number Publication date
JP2013501807A (ja) 2013-01-17
WO2011019932A9 (en) 2011-06-16
US8974788B2 (en) 2015-03-10
AU2010282415A1 (en) 2012-03-08
EP2464383A2 (en) 2012-06-20
WO2011019932A3 (en) 2011-08-18
US20110070235A1 (en) 2011-03-24
CA2771105A1 (en) 2011-02-17
EP2464383A4 (en) 2013-02-13
WO2011019932A2 (en) 2011-02-17
JP2015120738A (ja) 2015-07-02

Similar Documents

Publication Publication Date Title
US8916160B2 (en) Compositions and methods for the therapy and diagnosis of influenza
US8974788B2 (en) Compositions and methods for the therapy and diagnosis of influenza
US8900590B2 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
CN115315443A (zh) 抗sars-cov-2抗体和其用途
US20140363441A1 (en) Compositions and methods for the therapy and diagnosis of influenza
US20100178295A1 (en) Compositions and methods for the therapy and diagnosis of influenza
US8858948B2 (en) Compositions and methods for the therapy and diagnosis of influenza
US20130158238A1 (en) Compositions and Methods for the Therapy and Diagnosis of Influenza
KR20140012131A (ko) 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
KR20230038783A (ko) Sars-cov-2 단백질, 항-sars-cov-2 항체, 및 이를 사용하는 방법
NZ614215B2 (en) Compositions and methods for the therapy and diagnosis of influenza
HK40078886A (en) Anti-sars-cov-2 antibodies and uses thereof
CN116710555A (zh) 针对sars-cov-2的中和抗体
TW201031420A (en) Compositions and methods for the therapy and diagnosis of influenza
JPWO2015068781A1 (ja) インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
HK1195741A (en) Compositions and methods for the therapy and diagnosis of influenza